CAMP4 Therapeutics Corporation (CAMP) 10-Year Financial Performance & Capital Metrics

CAMP • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutCAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.Show more

Revenue $652K +86.3%
EBITDA -$51M -2.4%
Net Income -$52M -5.1%
EPS (Diluted) -2.66 +34.6%
Gross Margin 100%
EBITDA Margin -7882.21% +45.0%
Operating Margin -8142.33% +45.1%
Net Margin -7943.4% +43.6%
ROE -82.02%
ROIC -
Debt/Equity 0.14
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Negative free cash flow
✗Sales declining 71.8% over 5 years
✗Shares diluted 60.9% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-44.85%

5Y-71.81%

3Y-86.99%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM48.02%

ROCE

10Y Avg-17.84%

5Y Avg-38.62%

3Y Avg-62.41%

Latest-91.65%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Sales/Revenue+	280.72M	351.1M	365.91M	363.8M	366.11M	308.59M	295.84M	0	350K	652K
Revenue Growth %	0.12%	0.25%	0.04%	-0.01%	0.01%	-0.16%	-0.04%	-1%	-	0.86%
Cost of Goods Sold+	177.76M	207.75M	215.02M	216.04M	222.8M	186.18M	173.95M	0	0	0
COGS % of Revenue	0.63%	0.59%	0.59%	0.59%	0.61%	0.6%	0.59%	-	-	-
Gross Profit+	102.96M	143.35M	150.89M	147.76M	143.3M	122.41M	121.89M	0	350K	652K
Gross Margin %	0.37%	0.41%	0.41%	0.41%	0.39%	0.4%	0.41%	-	1%	1%
Gross Profit Growth %	0.18%	0.39%	0.05%	-0.02%	-0.03%	-0.15%	-0%	-1%	-	0.86%
Operating Expenses+	74.87M	142.01M	142.94M	120.05M	159.96M	125.87M	134.76M	45M	52.23M	53.74M
OpEx % of Revenue	0.27%	0.4%	0.39%	0.33%	0.44%	0.41%	0.46%	-	149.23%	82.42%
Selling, General & Admin	48.45M	104.94M	102.19M	80.96M	118.2M	95.28M	100.9M	10.23M	11.61M	14.92M
SG&A % of Revenue	0.17%	0.3%	0.28%	0.22%	0.32%	0.31%	0.34%	-	33.18%	22.89%
Research & Development	19.8M	22M	25.76M	27.66M	29.44M	25.81M	28.44M	34.77M	40.62M	38.82M
R&D % of Revenue	0.07%	0.06%	0.07%	0.08%	0.08%	0.08%	0.1%	-	116.05%	59.54%
Other Operating Expenses	-20K	-101K	445K	-672K	12.32M	4.78M	5.42M	0	0	0
Operating Income+	28.09M	1.34M	7.96M	19.7M	-16.77M	-3.87M	-15.31M	-45M	-51.88M	-53.09M
Operating Margin %	0.1%	0%	0.02%	0.05%	-0.05%	-0.01%	-0.05%	-	-148.23%	-81.42%
Operating Income Growth %	0.13%	-0.95%	4.93%	1.48%	-1.85%	0.77%	-2.96%	-1.94%	-0.15%	-0.02%
EBITDA+	38.29M	24.81M	30.91M	39.71M	15.22M	18.13M	7.49M	-44.12M	-50.2M	-51.39M
EBITDA Margin %	0.14%	0.07%	0.08%	0.11%	0.04%	0.06%	0.03%	-	-143.43%	-78.82%
EBITDA Growth %	0.12%	-0.35%	0.25%	0.28%	-0.62%	0.19%	-0.59%	-6.89%	-0.14%	-0.02%
D&A (Non-Cash Add-back)	10.21M	23.47M	22.96M	20.02M	31.99M	22M	22.8M	878K	1.68M	1.7M
EBIT	28.09M	0	0	0	-16.77M	-3.87M	-15.31M	-45M	-51.88M	-53.09M
Net Interest Income+	-7.59M	-9.9M	-10.28M	-16.73M	-20.1M	-15.49M	-15.32M	-6.26M	2.81M	1.33M
Interest Income	0	0	0	0	0	0	0	0	2.81M	1.33M
Interest Expense	7.59M	9.9M	10.28M	16.73M	20.1M	15.49M	15.32M	6.26M	0	0
Other Income/Expense	1.85M	1.59M	31.03M	12.87M	-41.55M	-16.73M	-14.75M	809K	2.59M	1.3M
Pretax Income+	22.34M	-6.96M	28.71M	23.86M	-58.32M	-20.6M	-30.06M	-44.19M	-49.29M	-51.79M
Pretax Margin %	0.08%	-0.02%	0.08%	0.07%	-0.16%	-0.07%	-0.1%	-	-140.83%	-79.43%
Income Tax+	4.57M	-1.1M	10.68M	-1.33M	20.45M	561K	1.09M	0	0	0
Effective Tax Rate %	0.76%	1.03%	0.58%	0.77%	1.35%	1.03%	1.04%	1%	1%	1%
Net Income+	16.94M	-7.15M	16.62M	18.4M	-78.77M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Net Margin %	0.06%	-0.02%	0.05%	0.05%	-0.22%	-0.07%	-0.11%	-	-140.83%	-79.43%
Net Income Growth %	0.03%	-1.42%	3.32%	0.11%	-5.28%	0.73%	-0.47%	-0.42%	-0.12%	-0.05%
Net Income (Continuing)	-	-	-	-	-78.77M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.46	-0.20	0.46	0.52	-2.34	-0.62	-0.88	-0.90	-4.07	-2.66
EPS Growth %	0.02%	-1.43%	3.3%	0.13%	-5.5%	0.74%	-0.42%	-0.02%	-3.52%	0.35%
EPS (Basic)	0.46	-0.20	0.47	0.53	-2.35	-0.62	-0.88	-0.90	-4.07	-2.66
Diluted Shares Outstanding	36.95M	35.92M	36.14M	35.29M	33.67M	34.39M	35.25M	36.13M	12.12M	19.51M
Basic Shares Outstanding	36.45M	35.92M	35.25M	34.59M	33.48M	34.12M	35.25M	36.1M	12.12M	19.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Total Current Assets+	298.77M	206.71M	275.88M	403.5M	237.87M	215.23M	193.59M	84.41M	40.01M	66.38M
Cash & Short-Term Investments	228.11M	100.43M	156M	274.01M	107.4M	91.69M	91.11M	83.19M	38.38M	64.04M
Cash Only	139.39M	93.71M	132.6M	256.5M	107.4M	91.69M	91.11M	83.19M	38.38M	64.04M
Short-Term Investments	88.72M	6.72M	23.4M	17.51M	0	0	0	0	0	0
Accounts Receivable	49.43M	67.4M	71.58M	78.08M	72.27M	67.85M	58.59M	678K	442K	108K
Days Sales Outstanding	64.27	70.07	71.4	78.34	72.05	80.26	72.29	-	460.94	60.46
Inventory	16.73M	29.28M	36.3M	32.03M	36.78M	32.16M	20.18M	0	0	0
Days Inventory Outstanding	34.35	51.44	61.62	54.12	60.25	63.05	42.34	-	-	-
Other Current Assets	4.5M	9.6M	12M	19.37M	21.41M	23.52M	23.7M	205K	245K	211K
Total Non-Current Assets+	85.6M	200.97M	197.11M	200.13M	257.94M	226.6M	208.7M	18.14M	14.93M	11.92M
Property, Plant & Equipment	11.22M	21.16M	21.26M	27.02M	76.5M	62.23M	50.06M	16.8M	13.31M	10.3M
Fixed Asset Turnover	25.01x	16.59x	17.21x	13.46x	4.79x	4.96x	5.91x	-	0.03x	0.06x
Goodwill	16.51M	72.98M	72.98M	80.81M	106.33M	94.47M	94M	0	0	0
Intangible Assets	17.01M	67.22M	52.46M	47.16M	45.9M	38.94M	33.01M	0	0	0
Long-Term Investments	6.63M	4.68M	8.84M	4.91M	0	24.16M	24.34M	0	0	0
Other Non-Current Assets	4.01M	7.88M	9.99M	17.6M	24.77M	2.36M	3.05M	1.35M	1.62M	1.62M
Total Assets+	384.36M	407.67M	472.99M	603.63M	495.81M	441.82M	402.29M	102.55M	54.95M	78.31M
Asset Turnover	0.73x	0.86x	0.77x	0.60x	0.74x	0.70x	0.74x	-	0.01x	0.01x
Asset Growth %	0.9%	0.06%	0.16%	0.28%	-0.18%	-0.11%	-0.09%	-0.75%	-0.46%	0.43%
Total Current Liabilities+	49.56M	76.62M	95.53M	83.59M	121.47M	107.38M	94.88M	7.95M	7.81M	9.6M
Accounts Payable	24.94M	30.27M	35.48M	39.9M	28.45M	36.83M	30.78M	2.15M	1.04M	1.21M
Days Payables Outstanding	51.21	53.17	60.22	67.41	46.61	72.21	64.58	-	-	-
Short-Term Debt	6.81M	10.98M	32.22M	36.84M	37.78M	10.94M	7.74M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0	385K
Other Current Liabilities	33.31M	52.2M	45.55M	22.48M	20.3M	20.68M	23.96M	1.78M	2.34M	3.2M
Current Ratio	6.03x	2.70x	2.89x	4.83x	1.96x	2.00x	2.04x	10.62x	5.13x	6.92x
Quick Ratio	5.69x	2.32x	2.51x	4.44x	1.66x	1.70x	1.83x	10.62x	5.13x	6.92x
Cash Conversion Cycle	47.42	68.34	72.8	65.05	85.7	71.1	50.04	-	-	-
Total Non-Current Liabilities+	145.35M	167.06M	178.55M	314.38M	236.41M	235.12M	227.23M	172.13M	170.87M	5.57M
Long-Term Debt	139.8M	146.83M	154.3M	275.9M	201.37M	199.86M	201.43M	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	10.03M	8.63M	5.56M
Deferred Tax Liabilities	-1.07M	-12.26M	-16.76M	963K	122K	6.96M	208K	0	0	0
Other Non-Current Liabilities	5.55M	20.23M	24.25M	38.48M	7.47M	4.08M	11.1M	162.11M	162.23M	2K
Total Liabilities	194.92M	243.68M	274.08M	397.97M	357.89M	342.5M	322.11M	180.08M	178.68M	15.16M
Total Debt+	139.8M	146.83M	154.3M	275.9M	234.49M	210.8M	209.17M	12.39M	11.69M	8.65M
Net Debt	412K	53.12M	21.7M	19.41M	127.08M	119.11M	118.05M	-70.8M	-26.69M	-55.39M
Debt / Equity	0.74x	0.90x	0.78x	1.34x	1.70x	2.12x	2.61x	-	-	0.14x
Debt / EBITDA	3.65x	5.92x	4.99x	6.95x	15.41x	11.63x	27.92x	-	-	-
Net Debt / EBITDA	0.01x	2.14x	0.70x	0.49x	8.35x	6.57x	15.76x	-	-	-
Interest Coverage	3.70x	0.14x	0.77x	1.18x	-0.83x	-0.25x	-1.00x	-7.19x	-	-
Total Equity+	189.45M	164M	198.92M	205.65M	137.92M	99.32M	80.18M	-77.53M	-123.73M	63.14M
Equity Growth %	0.25%	-0.13%	0.21%	0.03%	-0.33%	-0.28%	-0.19%	-1.97%	-0.6%	1.51%
Book Value per Share	5.13	4.57	5.50	5.83	4.10	2.89	2.27	-2.15	-10.20	3.24
Total Shareholders' Equity	189.45M	164M	198.92M	205.65M	137.92M	99.32M	80.18M	-77.53M	-123.73M	63.14M
Common Stock	367K	353K	357K	336K	343K	350K	359K	1K	1K	2K
Retained Earnings	-39.85M	-47M	-19.46M	-2.23M	-81.53M	-129.25M	-156.78M	-110.67M	-159.96M	-211.75M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-226K	-541K	-199K	-661K	-1.38M	-1.11M	-2.44M	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Cash from Operations+	47.4M	25.8M	66.89M	47.74M	11.54M	28.59M	-4.22M	-38.54M	-44.16M	-45.56M
Operating CF Margin %	0.17%	0.07%	0.18%	0.13%	0.03%	0.09%	-0.01%	-	-126.16%	-69.88%
Operating CF Growth %	0.65%	-0.46%	1.59%	-0.29%	-0.76%	1.48%	-1.15%	-8.14%	-0.15%	-0.03%
Net Income	16.94M	-7.15M	16.62M	18.4M	-51.55M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Depreciation & Amortization	10.21M	23.47M	22.96M	20.02M	23.31M	22M	22.8M	878K	1.68M	1.7M
Stock-Based Compensation	5.85M	7.83M	9.3M	11.03M	10.67M	11.36M	11.32M	1.38M	2.91M	4.03M
Deferred Taxes	4.12M	-2.27M	6.37M	-1.24M	18.55M	-1K	465K	0	0	0
Other Non-Cash Items	5.13M	7M	7.48M	11.86M	9.05M	5.03M	10.15M	1.69M	1.82M	1.83M
Working Capital Changes	5.73M	-5.73M	2.35M	-22.3M	-11.89M	14.93M	-17.42M	1.7M	-1.27M	-1.33M
Change in Receivables	-1.51M	3.09M	-6.45M	-4.86M	7.55M	1.62M	1.44M	0	0	0
Change in Inventory	1.94M	221K	-6.52M	5.43M	-1.44M	8.69M	5.16M	0	0	0
Change in Payables	926K	-4.62M	5.07M	1.88M	-17.6M	10.17M	-4.78M	1.33M	-1.11M	168K
Cash from Investing+	-90.67M	-45.59M	-26.45M	-21.79M	-65.7M	-13.69M	-7.58M	-4.03M	-678K	-441K
Capital Expenditures	0	0	0	0	0	0	0	-4.03M	-678K	-441K
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.06%	0.04%	0.04%	-	1.94%	0.68%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-110K	-2.64M	-2.42M	-2.74M	-366K	0	0	0	0	0
Cash from Financing+	148.48M	-25.82M	-2.26M	98.5M	-94.82M	-27.32M	-2.64M	100.16M	301K	71.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-23.27M	-1.78M	-2.59M	-28.95M	-2.01M	-1.63M	-4.17M	55K	623K	-4.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	43.08M	17.83M	58.55M	35.73M	-9.76M	17.23M	-17.52M	-42.57M	-44.83M	-46M
FCF Margin %	0.15%	0.05%	0.16%	0.1%	-0.03%	0.06%	-0.06%	-	-128.09%	-70.56%
FCF Growth %	1.03%	-0.59%	2.28%	-0.39%	-1.27%	2.77%	-2.02%	-1.43%	-0.05%	-0.03%
FCF per Share	1.17	0.50	1.62	1.01	-0.29	0.50	-0.50	-1.18	-3.70	-2.36
FCF Conversion (FCF/Net Income)	2.80x	-3.61x	4.03x	2.59x	-0.15x	-1.35x	0.14x	0.87x	0.90x	0.88x
Interest Paid	-	-	-	-	-	-	-	-	0	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	9.94%	-4.05%	9.16%	9.1%	-45.86%	-17.84%	-34.71%	-3335.25%	-	-82.02%
Return on Invested Capital (ROIC)	13.69%	0.49%	2.73%	6.63%	-5.13%	-1.2%	-5.51%	-135.25%	-	-
Gross Margin	36.68%	40.83%	41.24%	40.62%	39.14%	39.67%	41.2%	-	100%	100%
Net Margin	6.03%	-2.04%	4.54%	5.06%	-21.52%	-6.86%	-10.53%	-	-14083.14%	-7943.4%
Debt / Equity	0.74x	0.90x	0.78x	1.34x	1.70x	2.12x	2.61x	-	-	0.14x
Interest Coverage	3.70x	0.14x	0.77x	1.18x	-0.83x	-0.25x	-1.00x	-7.19x	-	-
FCF Conversion	2.80x	-3.61x	4.03x	2.59x	-0.15x	-1.35x	0.14x	0.87x	0.90x	0.88x
Revenue Growth	12.02%	25.07%	4.22%	-0.58%	0.63%	-15.71%	-4.13%	-100%	-	86.29%

Revenue by Segment

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Product	-	-	-	-	-	285.88M	-	193.49M	182.92M	188.88M
Product Growth	-	-	-	-	-	-	-	-	-5.46%	3.26%
Application Subscriptions And Other Services	-	-	-	-	-	-	-	115.1M	112.92M	106.07M
Application Subscriptions And Other Services Growth	-	-	-	-	-	-	-	-	-1.89%	-6.07%
Telematics Products	-	-	-	-	-	-	241.21M	-	-	-
Telematics Products Growth	-	-	-	-	-	-	-	-	-	-
Application Subscriptions And Related Products And Other Services	-	-	-	-	-	77.92M	124.89M	-	-	-
Application Subscriptions And Related Products And Other Services Growth	-	-	-	-	-	-	60.29%	-	-	-
Telematics Systems	-	-	-	-	302.13M	-	-	-	-	-
Telematics Systems Growth	-	-	-	-	-	-	-	-	-	-
Software And Subscription Services	-	-	-	-	63.79M	-	-	-	-	-
Software And Subscription Services Growth	-	-	-	-	-	-	-	-	-	-
Wireless Datacom	187.01M	213.12M	241.39M	336.03M	-	-	-	-	-	-
Wireless Datacom Growth	-	13.96%	13.26%	39.21%	-	-	-	-	-	-
Satellite	48.89M	37.49M	39.33M	15.07M	-	-	-	-	-	-
Satellite Growth	-	-23.33%	4.92%	-61.69%	-	-	-	-	-	-

Revenue by Geography

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
UNITED STATES	-	-	-	-	265.61M	268.45M	266.41M	200.66M	197.18M	185.47M
UNITED STATES Growth	-	-	-	-	-	1.07%	-0.76%	-24.68%	-1.74%	-5.94%
EMEA	-	-	-	-	-	-	-	-	-	54.7M
EMEA Growth	-	-	-	-	-	-	-	-	-	-
Latin America	-	-	-	-	-	-	-	-	-	32.01M
Latin America Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	12.87M	13.96M	9.17M	12.28M	19.03M	18.45M
Asia Pacific Growth	-	-	-	-	-	8.43%	-34.33%	33.98%	54.94%	-3.04%
All Other	-	-	-	-	5.94M	6.94M	14.11M	10.06M	3.1M	4.33M
All Other Growth	-	-	-	-	-	16.92%	103.17%	-28.69%	-69.17%	39.46%
E M E A	-	-	-	-	-	49.5M	55.19M	58.47M	51.77M	-
E M E A Growth	-	-	-	-	-	-	11.49%	5.95%	-11.46%	-
L A S F	-	-	-	-	-	-	-	-	24.76M	-
L A S F Growth	-	-	-	-	-	-	-	-	-	-
South America	-	-	-	-	20.7M	15.13M	21.23M	27.11M	-	-
South America Growth	-	-	-	-	-	-26.89%	40.31%	27.67%	-	-
CANADA	-	-	-	-	14.96M	9.81M	-	-	-	-
CANADA Growth	-	-	-	-	-	-34.38%	-	-	-	-
Europe Middle East And Africa	-	-	-	-	45.83M	-	-	-	-	-
Europe Middle East And Africa Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CAMP4 Therapeutics Corporation (CAMP) reported $3.8M in revenue for fiscal year 2024. This represents a 97% decrease from $138.7M in 2011.

CAMP4 Therapeutics Corporation (CAMP) grew revenue by 86.3% over the past year. This is strong growth.

CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $53.4M for fiscal year 2024.

Dividend & Returns

CAMP4 Therapeutics Corporation (CAMP) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.

CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $47.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

CAMP4 Therapeutics Corporation (CAMP) 10-Year Financial Performance & Capital Metrics

CAMP • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $652K +86.3%
EBITDA -$51M -2.4%
Net Income -$52M -5.1%
EPS (Diluted) -2.66 +34.6%
Gross Margin 100%
EBITDA Margin -7882.21% +45.0%
Operating Margin -8142.33% +45.1%
Net Margin -7943.4% +43.6%
ROE -82.02%
ROIC -
Debt/Equity 0.14
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Negative free cash flow
✗Sales declining 71.8% over 5 years
✗Shares diluted 60.9% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-44.85%

5Y-71.81%

3Y-86.99%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM48.02%

ROCE

10Y Avg-17.84%

5Y Avg-38.62%

3Y Avg-62.41%

Latest-91.65%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Sales/Revenue+	280.72M	351.1M	365.91M	363.8M	366.11M	308.59M	295.84M	0	350K	652K
Revenue Growth %	0.12%	0.25%	0.04%	-0.01%	0.01%	-0.16%	-0.04%	-1%	-	0.86%
Cost of Goods Sold+	177.76M	207.75M	215.02M	216.04M	222.8M	186.18M	173.95M	0	0	0
COGS % of Revenue	0.63%	0.59%	0.59%	0.59%	0.61%	0.6%	0.59%	-	-	-
Gross Profit+	102.96M	143.35M	150.89M	147.76M	143.3M	122.41M	121.89M	0	350K	652K
Gross Margin %	0.37%	0.41%	0.41%	0.41%	0.39%	0.4%	0.41%	-	1%	1%
Gross Profit Growth %	0.18%	0.39%	0.05%	-0.02%	-0.03%	-0.15%	-0%	-1%	-	0.86%
Operating Expenses+	74.87M	142.01M	142.94M	120.05M	159.96M	125.87M	134.76M	45M	52.23M	53.74M
OpEx % of Revenue	0.27%	0.4%	0.39%	0.33%	0.44%	0.41%	0.46%	-	149.23%	82.42%
Selling, General & Admin	48.45M	104.94M	102.19M	80.96M	118.2M	95.28M	100.9M	10.23M	11.61M	14.92M
SG&A % of Revenue	0.17%	0.3%	0.28%	0.22%	0.32%	0.31%	0.34%	-	33.18%	22.89%
Research & Development	19.8M	22M	25.76M	27.66M	29.44M	25.81M	28.44M	34.77M	40.62M	38.82M
R&D % of Revenue	0.07%	0.06%	0.07%	0.08%	0.08%	0.08%	0.1%	-	116.05%	59.54%
Other Operating Expenses	-20K	-101K	445K	-672K	12.32M	4.78M	5.42M	0	0	0
Operating Income+	28.09M	1.34M	7.96M	19.7M	-16.77M	-3.87M	-15.31M	-45M	-51.88M	-53.09M
Operating Margin %	0.1%	0%	0.02%	0.05%	-0.05%	-0.01%	-0.05%	-	-148.23%	-81.42%
Operating Income Growth %	0.13%	-0.95%	4.93%	1.48%	-1.85%	0.77%	-2.96%	-1.94%	-0.15%	-0.02%
EBITDA+	38.29M	24.81M	30.91M	39.71M	15.22M	18.13M	7.49M	-44.12M	-50.2M	-51.39M
EBITDA Margin %	0.14%	0.07%	0.08%	0.11%	0.04%	0.06%	0.03%	-	-143.43%	-78.82%
EBITDA Growth %	0.12%	-0.35%	0.25%	0.28%	-0.62%	0.19%	-0.59%	-6.89%	-0.14%	-0.02%
D&A (Non-Cash Add-back)	10.21M	23.47M	22.96M	20.02M	31.99M	22M	22.8M	878K	1.68M	1.7M
EBIT	28.09M	0	0	0	-16.77M	-3.87M	-15.31M	-45M	-51.88M	-53.09M
Net Interest Income+	-7.59M	-9.9M	-10.28M	-16.73M	-20.1M	-15.49M	-15.32M	-6.26M	2.81M	1.33M
Interest Income	0	0	0	0	0	0	0	0	2.81M	1.33M
Interest Expense	7.59M	9.9M	10.28M	16.73M	20.1M	15.49M	15.32M	6.26M	0	0
Other Income/Expense	1.85M	1.59M	31.03M	12.87M	-41.55M	-16.73M	-14.75M	809K	2.59M	1.3M
Pretax Income+	22.34M	-6.96M	28.71M	23.86M	-58.32M	-20.6M	-30.06M	-44.19M	-49.29M	-51.79M
Pretax Margin %	0.08%	-0.02%	0.08%	0.07%	-0.16%	-0.07%	-0.1%	-	-140.83%	-79.43%
Income Tax+	4.57M	-1.1M	10.68M	-1.33M	20.45M	561K	1.09M	0	0	0
Effective Tax Rate %	0.76%	1.03%	0.58%	0.77%	1.35%	1.03%	1.04%	1%	1%	1%
Net Income+	16.94M	-7.15M	16.62M	18.4M	-78.77M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Net Margin %	0.06%	-0.02%	0.05%	0.05%	-0.22%	-0.07%	-0.11%	-	-140.83%	-79.43%
Net Income Growth %	0.03%	-1.42%	3.32%	0.11%	-5.28%	0.73%	-0.47%	-0.42%	-0.12%	-0.05%
Net Income (Continuing)	-	-	-	-	-78.77M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.46	-0.20	0.46	0.52	-2.34	-0.62	-0.88	-0.90	-4.07	-2.66
EPS Growth %	0.02%	-1.43%	3.3%	0.13%	-5.5%	0.74%	-0.42%	-0.02%	-3.52%	0.35%
EPS (Basic)	0.46	-0.20	0.47	0.53	-2.35	-0.62	-0.88	-0.90	-4.07	-2.66
Diluted Shares Outstanding	36.95M	35.92M	36.14M	35.29M	33.67M	34.39M	35.25M	36.13M	12.12M	19.51M
Basic Shares Outstanding	36.45M	35.92M	35.25M	34.59M	33.48M	34.12M	35.25M	36.1M	12.12M	19.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Total Current Assets+	298.77M	206.71M	275.88M	403.5M	237.87M	215.23M	193.59M	84.41M	40.01M	66.38M
Cash & Short-Term Investments	228.11M	100.43M	156M	274.01M	107.4M	91.69M	91.11M	83.19M	38.38M	64.04M
Cash Only	139.39M	93.71M	132.6M	256.5M	107.4M	91.69M	91.11M	83.19M	38.38M	64.04M
Short-Term Investments	88.72M	6.72M	23.4M	17.51M	0	0	0	0	0	0
Accounts Receivable	49.43M	67.4M	71.58M	78.08M	72.27M	67.85M	58.59M	678K	442K	108K
Days Sales Outstanding	64.27	70.07	71.4	78.34	72.05	80.26	72.29	-	460.94	60.46
Inventory	16.73M	29.28M	36.3M	32.03M	36.78M	32.16M	20.18M	0	0	0
Days Inventory Outstanding	34.35	51.44	61.62	54.12	60.25	63.05	42.34	-	-	-
Other Current Assets	4.5M	9.6M	12M	19.37M	21.41M	23.52M	23.7M	205K	245K	211K
Total Non-Current Assets+	85.6M	200.97M	197.11M	200.13M	257.94M	226.6M	208.7M	18.14M	14.93M	11.92M
Property, Plant & Equipment	11.22M	21.16M	21.26M	27.02M	76.5M	62.23M	50.06M	16.8M	13.31M	10.3M
Fixed Asset Turnover	25.01x	16.59x	17.21x	13.46x	4.79x	4.96x	5.91x	-	0.03x	0.06x
Goodwill	16.51M	72.98M	72.98M	80.81M	106.33M	94.47M	94M	0	0	0
Intangible Assets	17.01M	67.22M	52.46M	47.16M	45.9M	38.94M	33.01M	0	0	0
Long-Term Investments	6.63M	4.68M	8.84M	4.91M	0	24.16M	24.34M	0	0	0
Other Non-Current Assets	4.01M	7.88M	9.99M	17.6M	24.77M	2.36M	3.05M	1.35M	1.62M	1.62M
Total Assets+	384.36M	407.67M	472.99M	603.63M	495.81M	441.82M	402.29M	102.55M	54.95M	78.31M
Asset Turnover	0.73x	0.86x	0.77x	0.60x	0.74x	0.70x	0.74x	-	0.01x	0.01x
Asset Growth %	0.9%	0.06%	0.16%	0.28%	-0.18%	-0.11%	-0.09%	-0.75%	-0.46%	0.43%
Total Current Liabilities+	49.56M	76.62M	95.53M	83.59M	121.47M	107.38M	94.88M	7.95M	7.81M	9.6M
Accounts Payable	24.94M	30.27M	35.48M	39.9M	28.45M	36.83M	30.78M	2.15M	1.04M	1.21M
Days Payables Outstanding	51.21	53.17	60.22	67.41	46.61	72.21	64.58	-	-	-
Short-Term Debt	6.81M	10.98M	32.22M	36.84M	37.78M	10.94M	7.74M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0	385K
Other Current Liabilities	33.31M	52.2M	45.55M	22.48M	20.3M	20.68M	23.96M	1.78M	2.34M	3.2M
Current Ratio	6.03x	2.70x	2.89x	4.83x	1.96x	2.00x	2.04x	10.62x	5.13x	6.92x
Quick Ratio	5.69x	2.32x	2.51x	4.44x	1.66x	1.70x	1.83x	10.62x	5.13x	6.92x
Cash Conversion Cycle	47.42	68.34	72.8	65.05	85.7	71.1	50.04	-	-	-
Total Non-Current Liabilities+	145.35M	167.06M	178.55M	314.38M	236.41M	235.12M	227.23M	172.13M	170.87M	5.57M
Long-Term Debt	139.8M	146.83M	154.3M	275.9M	201.37M	199.86M	201.43M	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	10.03M	8.63M	5.56M
Deferred Tax Liabilities	-1.07M	-12.26M	-16.76M	963K	122K	6.96M	208K	0	0	0
Other Non-Current Liabilities	5.55M	20.23M	24.25M	38.48M	7.47M	4.08M	11.1M	162.11M	162.23M	2K
Total Liabilities	194.92M	243.68M	274.08M	397.97M	357.89M	342.5M	322.11M	180.08M	178.68M	15.16M
Total Debt+	139.8M	146.83M	154.3M	275.9M	234.49M	210.8M	209.17M	12.39M	11.69M	8.65M
Net Debt	412K	53.12M	21.7M	19.41M	127.08M	119.11M	118.05M	-70.8M	-26.69M	-55.39M
Debt / Equity	0.74x	0.90x	0.78x	1.34x	1.70x	2.12x	2.61x	-	-	0.14x
Debt / EBITDA	3.65x	5.92x	4.99x	6.95x	15.41x	11.63x	27.92x	-	-	-
Net Debt / EBITDA	0.01x	2.14x	0.70x	0.49x	8.35x	6.57x	15.76x	-	-	-
Interest Coverage	3.70x	0.14x	0.77x	1.18x	-0.83x	-0.25x	-1.00x	-7.19x	-	-
Total Equity+	189.45M	164M	198.92M	205.65M	137.92M	99.32M	80.18M	-77.53M	-123.73M	63.14M
Equity Growth %	0.25%	-0.13%	0.21%	0.03%	-0.33%	-0.28%	-0.19%	-1.97%	-0.6%	1.51%
Book Value per Share	5.13	4.57	5.50	5.83	4.10	2.89	2.27	-2.15	-10.20	3.24
Total Shareholders' Equity	189.45M	164M	198.92M	205.65M	137.92M	99.32M	80.18M	-77.53M	-123.73M	63.14M
Common Stock	367K	353K	357K	336K	343K	350K	359K	1K	1K	2K
Retained Earnings	-39.85M	-47M	-19.46M	-2.23M	-81.53M	-129.25M	-156.78M	-110.67M	-159.96M	-211.75M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-226K	-541K	-199K	-661K	-1.38M	-1.11M	-2.44M	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Feb 2016	Feb 2017	Feb 2018	Feb 2019	Feb 2020	Feb 2021	Feb 2022	Feb 2023	Nov 2023	Dec 2024
Cash from Operations+	47.4M	25.8M	66.89M	47.74M	11.54M	28.59M	-4.22M	-38.54M	-44.16M	-45.56M
Operating CF Margin %	0.17%	0.07%	0.18%	0.13%	0.03%	0.09%	-0.01%	-	-126.16%	-69.88%
Operating CF Growth %	0.65%	-0.46%	1.59%	-0.29%	-0.76%	1.48%	-1.15%	-8.14%	-0.15%	-0.03%
Net Income	16.94M	-7.15M	16.62M	18.4M	-51.55M	-21.16M	-31.15M	-44.19M	-49.29M	-51.79M
Depreciation & Amortization	10.21M	23.47M	22.96M	20.02M	23.31M	22M	22.8M	878K	1.68M	1.7M
Stock-Based Compensation	5.85M	7.83M	9.3M	11.03M	10.67M	11.36M	11.32M	1.38M	2.91M	4.03M
Deferred Taxes	4.12M	-2.27M	6.37M	-1.24M	18.55M	-1K	465K	0	0	0
Other Non-Cash Items	5.13M	7M	7.48M	11.86M	9.05M	5.03M	10.15M	1.69M	1.82M	1.83M
Working Capital Changes	5.73M	-5.73M	2.35M	-22.3M	-11.89M	14.93M	-17.42M	1.7M	-1.27M	-1.33M
Change in Receivables	-1.51M	3.09M	-6.45M	-4.86M	7.55M	1.62M	1.44M	0	0	0
Change in Inventory	1.94M	221K	-6.52M	5.43M	-1.44M	8.69M	5.16M	0	0	0
Change in Payables	926K	-4.62M	5.07M	1.88M	-17.6M	10.17M	-4.78M	1.33M	-1.11M	168K
Cash from Investing+	-90.67M	-45.59M	-26.45M	-21.79M	-65.7M	-13.69M	-7.58M	-4.03M	-678K	-441K
Capital Expenditures	0	0	0	0	0	0	0	-4.03M	-678K	-441K
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.06%	0.04%	0.04%	-	1.94%	0.68%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-110K	-2.64M	-2.42M	-2.74M	-366K	0	0	0	0	0
Cash from Financing+	148.48M	-25.82M	-2.26M	98.5M	-94.82M	-27.32M	-2.64M	100.16M	301K	71.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-23.27M	-1.78M	-2.59M	-28.95M	-2.01M	-1.63M	-4.17M	55K	623K	-4.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	43.08M	17.83M	58.55M	35.73M	-9.76M	17.23M	-17.52M	-42.57M	-44.83M	-46M
FCF Margin %	0.15%	0.05%	0.16%	0.1%	-0.03%	0.06%	-0.06%	-	-128.09%	-70.56%
FCF Growth %	1.03%	-0.59%	2.28%	-0.39%	-1.27%	2.77%	-2.02%	-1.43%	-0.05%	-0.03%
FCF per Share	1.17	0.50	1.62	1.01	-0.29	0.50	-0.50	-1.18	-3.70	-2.36
FCF Conversion (FCF/Net Income)	2.80x	-3.61x	4.03x	2.59x	-0.15x	-1.35x	0.14x	0.87x	0.90x	0.88x
Interest Paid	-	-	-	-	-	-	-	-	0	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	9.94%	-4.05%	9.16%	9.1%	-45.86%	-17.84%	-34.71%	-3335.25%	-	-82.02%
Return on Invested Capital (ROIC)	13.69%	0.49%	2.73%	6.63%	-5.13%	-1.2%	-5.51%	-135.25%	-	-
Gross Margin	36.68%	40.83%	41.24%	40.62%	39.14%	39.67%	41.2%	-	100%	100%
Net Margin	6.03%	-2.04%	4.54%	5.06%	-21.52%	-6.86%	-10.53%	-	-14083.14%	-7943.4%
Debt / Equity	0.74x	0.90x	0.78x	1.34x	1.70x	2.12x	2.61x	-	-	0.14x
Interest Coverage	3.70x	0.14x	0.77x	1.18x	-0.83x	-0.25x	-1.00x	-7.19x	-	-
FCF Conversion	2.80x	-3.61x	4.03x	2.59x	-0.15x	-1.35x	0.14x	0.87x	0.90x	0.88x
Revenue Growth	12.02%	25.07%	4.22%	-0.58%	0.63%	-15.71%	-4.13%	-100%	-	86.29%

Revenue by Segment

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Product	-	-	-	-	-	285.88M	-	193.49M	182.92M	188.88M
Product Growth	-	-	-	-	-	-	-	-	-5.46%	3.26%
Application Subscriptions And Other Services	-	-	-	-	-	-	-	115.1M	112.92M	106.07M
Application Subscriptions And Other Services Growth	-	-	-	-	-	-	-	-	-1.89%	-6.07%
Telematics Products	-	-	-	-	-	-	241.21M	-	-	-
Telematics Products Growth	-	-	-	-	-	-	-	-	-	-
Application Subscriptions And Related Products And Other Services	-	-	-	-	-	77.92M	124.89M	-	-	-
Application Subscriptions And Related Products And Other Services Growth	-	-	-	-	-	-	60.29%	-	-	-
Telematics Systems	-	-	-	-	302.13M	-	-	-	-	-
Telematics Systems Growth	-	-	-	-	-	-	-	-	-	-
Software And Subscription Services	-	-	-	-	63.79M	-	-	-	-	-
Software And Subscription Services Growth	-	-	-	-	-	-	-	-	-	-
Wireless Datacom	187.01M	213.12M	241.39M	336.03M	-	-	-	-	-	-
Wireless Datacom Growth	-	13.96%	13.26%	39.21%	-	-	-	-	-	-
Satellite	48.89M	37.49M	39.33M	15.07M	-	-	-	-	-	-
Satellite Growth	-	-23.33%	4.92%	-61.69%	-	-	-	-	-	-

Revenue by Geography

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
UNITED STATES	-	-	-	-	265.61M	268.45M	266.41M	200.66M	197.18M	185.47M
UNITED STATES Growth	-	-	-	-	-	1.07%	-0.76%	-24.68%	-1.74%	-5.94%
EMEA	-	-	-	-	-	-	-	-	-	54.7M
EMEA Growth	-	-	-	-	-	-	-	-	-	-
Latin America	-	-	-	-	-	-	-	-	-	32.01M
Latin America Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	12.87M	13.96M	9.17M	12.28M	19.03M	18.45M
Asia Pacific Growth	-	-	-	-	-	8.43%	-34.33%	33.98%	54.94%	-3.04%
All Other	-	-	-	-	5.94M	6.94M	14.11M	10.06M	3.1M	4.33M
All Other Growth	-	-	-	-	-	16.92%	103.17%	-28.69%	-69.17%	39.46%
E M E A	-	-	-	-	-	49.5M	55.19M	58.47M	51.77M	-
E M E A Growth	-	-	-	-	-	-	11.49%	5.95%	-11.46%	-
L A S F	-	-	-	-	-	-	-	-	24.76M	-
L A S F Growth	-	-	-	-	-	-	-	-	-	-
South America	-	-	-	-	20.7M	15.13M	21.23M	27.11M	-	-
South America Growth	-	-	-	-	-	-26.89%	40.31%	27.67%	-	-
CANADA	-	-	-	-	14.96M	9.81M	-	-	-	-
CANADA Growth	-	-	-	-	-	-34.38%	-	-	-	-
Europe Middle East And Africa	-	-	-	-	45.83M	-	-	-	-	-
Europe Middle East And Africa Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CAMP4 Therapeutics Corporation (CAMP) reported $3.8M in revenue for fiscal year 2024. This represents a 97% decrease from $138.7M in 2011.

CAMP4 Therapeutics Corporation (CAMP) grew revenue by 86.3% over the past year. This is strong growth.

CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $53.4M for fiscal year 2024.

Dividend & Returns

CAMP4 Therapeutics Corporation (CAMP) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.

CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $47.7M in fiscal year 2024, likely due to heavy capital investments.